An update from Polyrizon Ltd. ( (PLRZ) ) is now available.

Investing.com -- Polyrizon Ltd. (NASDAQ: PLRZ) stock surged 41% following the announcement of encouraging preclinical results for its PL-14 Allergy Blocker, which demonstrated targeted deposition in ...

Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the ...

Following a surge of 52.47% during regular trading session on Tuesday, Polyrizon Ltd (NASDAQ: PLRZ) witnessed a dip of 12.02% ...

Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially ...

Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...

RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ) has received approval from the Nasdaq Hearings Panel to maintain its listing on the Nasdaq Capital Market, the biotech company announced Tuesday.

Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap ...

Polyrizon (PLRZ) said on Tuesday that it has received a notification letter from Nasdaq granting the company’s request for the continued listing of its securities on the Nasdaq Capital Market.

RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ) has received approval from the Nasdaq Hearings Panel to maintain its listing on the Nasdaq Capital Market, the biotech company announced Tuesday ...

Raanana, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the 'Company” or 'Polyrizon”), a development stage biotech company specializing in the development of innovative ...